John Buse, MD, PhD

Articles by John Buse, MD, PhD

High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

ByGiuliana Grossi,Christian Ruff, MD,John Buse, MD, PhD,Marc P. Bonaca, MD, MPH,Marc Humbert, MD, PhD,Jawad Haider Butt, MD, PhD,Siddharth M. Patel, MD, MPH

April 4th 2025

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.

SOUL Findings Highlight Cardiovascular Benefits Beyond Glycemic Control With Oral GLP-1

ByGiuliana Grossi,John Buse, MD, PhD

March 30th 2025

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.